Trial Profile
A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2016
Price :
$35
*
At a glance
- Drugs Rocapuldencel T (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Argos Therapeutics Inc
- 07 Mar 2010 Results of this trial were present at the ASCO Genitourinary Cancers Symposium 2010.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.